Hemophilia

BOSTON and LONDON, July 10, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines…

The FDA approved valoctocogene roxaparvovec (Roctavian) as the first gene…

LEXINGTON, Mass. and AMSTERDAM, June 20, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe…

Elana Gotkine THURSDAY, March 30, 2023 (HealthDay News) -- For males aged 12 years or older with severe hemophilia A or B with or without inhibitors,…

A single infusion of the gene therapy valoctocogene roxaparvovec led to significantly…

The FDA has approved the recombinant antihemophilic factor Fc-VWF-XTEN fusion protein-ehtl…

<!-- Name:DistributionId Value:8754474 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8753147 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

Treatment with investigational efanesoctocog alfa (formerly BIVV001) -- a new class of…

LEXINGTON, Mass. and AMSTERDAM, Dec. 16, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe…